Company Profile

Lyra Therapeutics Inc (AKA: WMR Biomedical~480 Biomedical Inc~Arsenal Medical)
Profile last edited on: 12/2/2023      CAGE: 4PDS1      UEI: DK48JGAVNMJ1

Business Identifier: Clinical-stage company developing treatments for ear, nose, and throat diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

480 Arsenal Street Suite 4
Watertown, MA 02472
   (617) 393-4600
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

Founded as 480 Biomedical, Inc. by Drs Whitesides and Langer - well-known academic luminaries in the fields of chemistry, materials science and biotechnology - in 2018 the firm was renamed Lyra Therapeutics. Spun off from cardiovascular device developer Arsenal Medical Inc. and organized around developing a clinical-stage bioresorbable scaffold for occlusive disease in the superficial femoral artery, the firm is structured around using materials engineering to bring life-changing therapies to patients. Creating precisely tuned medicines designed to enable patients to breathe freely, the firm is working on a new therapeutic approach to treat debilitating ear, nose and throat diseases that impact the lives of millions of people. With the objective of transforming the ENT treatment paradigm- providing effective front-line solutions for physicians and new treatment options for their patients - Lyra’s transmucosal therapeutic system - being evaluated in a clinical study - directly targets tissues that are difficult or impossible to access with existing therapies. The Lyra team has developed a proprietary platform that enables sustained, local delivery of medications over an extended period of time. Clinical results, so far indicated this new therapeutic approach has the potential to provide significantly improved patient outcomes beyond the limited treatment and surgical options currently available for ENT diseases. Well funded from its early days, in late April 2020 the firm listed its anounced IPO objective for some $52.5M

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Duke Collier -- CEO

  Maria Palasis -- President and Chief Executive Officer

  Rashida S Ferebee

  Robert Langer -- Founder

  Pamela Nelson -- Senior VP, Senior VP, Regulatory Affairs

  Richard Nieman -- Chief Medical Officer

  Robert Palladino -- Chief Financial Officer

  Carmichael Roberts -- Founder

  Upma Sharma -- Senior Director of Research and Development

  George Whitesides -- Founder

Company News

There are no news available.